TAMOXIFEN-INDUCED DNA-ADDUCTS IN ENDOMETRIAL SAMPLES FROM BREAST-CANCER PATIENTS

Tamoxifen-induced DNA adducts were analyzed with the P-32-postlabeling method using high-performance liquid chromatography (HPLC)-radioactiv ity detection from endometrial tissue of breast cancer patients and co ntrols. Liver DNA from tamoxifen-treated rats was used as a positive s tandard, in blind analysis, five of the seven samples from tamoxifen-t reated patients showed DNA adducts; none of the five controls were pos itive. The identity of the tamoxifen adduct was confirmed by using dif ferent chromatographic systems, isolating the HPLC fractions and runni ng them on TLC, with or without spiked rat liver samples. The level of adducts in the treated patients was 2.7 adducts/10(9) nucleotides in the HPLC analysis.